AC is better than EDI for LC visibility

Article

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research.

If the goal is to improve lamina cribrosa (LC) visibility, adaptive compensation (AC) is better than enhanced depth imaging (EDI), according to new research published in Investigative Ophthalmology and Visual Science. Visibility of the posterior LC remains poor, so it is probably not realistic to use LC thickness as a glaucoma biomarker.

The researchers, from Singapore, French Polynesia and London, compared LC visibility in optic disc images obtained from 60 patients with glaucoma and 60 patients serving as controls. They used three optical coherence tomography (OCT) devices, with and without EDI and AC: They obtained a horizontal B-scan through the centre of the disc using two spectral-domain OCT devices (Spectralis, Heidelberg Engineering; Cirrus, Carl Zeiss Meditec - both with and without EDI) and a swept-source OCT device (DRI, Topcon). The investigators applied AC after they obtained the scans, to improve image quality.

Four masked observers evaluated LC visibility by grading the 1,200 images in random order. They graded the anterior LC on a 0-to-4 scale, the LC insertions on a scale of 0 to 2, and the posterior LC either as 0 or 1. The observers used generalized estimating equations to evaluate the effect on LC visibility of EDI, AC, glaucoma severity and other clinical and demographic factors.

The observers found that anterior LC was the most detectable feature, then LC insertions. “AC improved anterior LC visibility independent of EDI,” they wrote. “Cirrus+EDI+AC generated the greatest anterior LC visibility grades.”

Regarding LC insertions visibility, they said, “DRI+AC was the best method. Visibility of the posterior LC was consistently poor. Neither glaucoma severity nor clinical/demographic factors consistently affected LC visibility.”

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.